Predictors of the early impairment of renal disease in human obesity

International Journal of Obesity

Volumn 34, Issue 2, 2010, Pages 287-294

  Gilardini, L ^a   Zulian, A ^a   Girola, A ^a   Redaelli, G ^a   Conti, A ^a   Invitti, C ^a  

^a ISTITUTO AUXOLOGICO ITALIANO   (Italy)

Author keywords

Adipose tissue; Glucose homeostasis; Microalbuminuria; PTX 3; SOCS 3; Weight loss

Indexed keywords

ADIPONECTIN; ANGIOTENSINOGEN; CHOLESTEROL; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE; GLUCOSE; INTERLEUKIN 6; LIPID; MESSENGER RNA; PENTRAXIN 3; RNA; SUPPRESSOR OF CYTOKINE SIGNALING 3; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; ALBUMINOID; C REACTIVE PROTEIN; SERUM AMYLOID P; SOCS3 PROTEIN, HUMAN; SUPPRESSOR OF CYTOKINE SIGNALING;

ADIPOSE TISSUE; ADULT; ALBUMIN EXCRETION RATE; ANTHROPOMETRIC PARAMETERS; ANTHROPOMETRY; ARTICLE; BIOPSY; BLOOD PRESSURE; BLOOD SAMPLING; BODY MASS; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; FEMALE; GENE EXPRESSION; GLOMERULUS FILTRATION; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HOMEOSTASIS; HUMAN; INSULIN RESISTANCE; KIDNEY DISEASE; LIFESTYLE MODIFICATION; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MICROALBUMINURIA; OBESITY; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RNA ANALYSIS; TISSUE; TRIACYLGLYCEROL BLOOD LEVEL; URINARY EXCRETION; WAIST CIRCUMFERENCE; WEIGHT REDUCTION; ALBUMINURIA; COMPLICATION; GENETICS; METABOLISM; MIDDLE AGED; PHYSIOLOGY; PREDICTIVE VALUE; RISK REDUCTION; SECRETION (PROCESS); SUBCUTANEOUS FAT; URINE;

ADIPONECTIN; ALBUMINS; ALBUMINURIA; ANGIOTENSINOGEN; BODY MASS INDEX; C-REACTIVE PROTEIN; FEMALE; GENE EXPRESSION; HUMANS; INSULIN RESISTANCE; MIDDLE AGED; OBESITY; PEPTIDYL-DIPEPTIDASE A; PREDICTIVE VALUE OF TESTS; RISK REDUCTION BEHAVIOR; SERUM AMYLOID P-COMPONENT; SUBCUTANEOUS FAT; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS; TUMOR NECROSIS FACTOR-ALPHA; WEIGHT LOSS;

EID: 76749098752     PISSN: 03070565     EISSN: 14765497     Source Type: Journal    
DOI: 10.1038/ijo.2009.227     Document Type: Article

References (47)

1. Valensi P, Assayag M, Busby M, Pariès J, Lormeau B, Attali JR. Microalbuminuria in obese patients with or without hypertension. Int J Obes Relat Metab Disord 1996; 20: 574-579.
2. Verhave JC, Gansevoort RT, Hillege HL, Bakker SJ, De Zeeuw D, de Jong PE, PREVEND Study Group. An elevated urinary albumin excretion predicts de novo development of renal function impairment in the general population. Kidney Int Suppl 2004; 92: S18-S21.
3. Wachtell K, Ibsen H, Olsen MH, Borch-Johnsen K, Lindholm LH, Mogensen CE et al. Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. Ann Intern Med 2003; 139: 901-906.
4. Arnlöv J, Evans JC, Meigs JB, Wang TJ, Fox CS, Levy D et al. Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: the Framing-ham Heart Study. Circulation 2005; 112: 969-975.
5. Liese AD, Hense HW, Döring A, Stieber J, Keil U. Microalbumi-nuria, central adiposity and hypertension in the non-diabetic urban population of the MONICA Augsburg survey 1994/95. J Hum Hypertens 2001; 15: 799-804.
6. Solbu MD, Kronborg J, Eriksen BO, Jenssen TG, Toft I. Cardiovascular risk-factors predict progression of urinary albumin-excretion in a general, non-diabetic population: a gender-specific follow-up study. Atherosclerosis 2008; 201: 398-406.
7. Bonnet F, Marre M, Halimi JM, Stengel B, Lange C, Laville M et al. Waist circumference and the metabolic syndrome predict the development of elevated albuminuria in non-diabetic subjects: the DESIR Study. J Hypertens 2006; 24: 1157-1163.
8. Bello AK, de Zeeuw D, El Nahas M, Brantsma AH, Bakker SJ, de Jong PE et al. Impact of weight change on albuminuria in the general population. Nephrol Dial Transplant 2007; 22: 1619-1627.
9. Prospective Studies Collaboration, Whitlock G, Lewington S, Sherliker P, Clarke R, Emberson J, Halsey J et al. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet 2009; 373: 1083-1096.
10. Chagnac A, Weinstein T, Korzets A, Ramadan E, Hirsch J, Gafter U. Glomerular hemodynamics in severe obesity. Am J Physiol Renal Physiol 2000; 278: F817-F822.
11. Chagnac A, Weinstein T, Herman M, Hirsh J, Gafter U, Ori Y. The effects of weight loss on renal function in patients with severe obesity. J Am Soc Nephrol 2003; 14: 1480-1486.
12. Cubeddu LX, Alfieri AB, Hoffmann IS. Lowering the threshold for defining microalbuminuria: effects of a lifestyle-metformin intervention in obese 'normoalbuminuric' non-diabetic subjects. Am J Hypertens 2008; 21: 1005-1010.
13. Shikano M, Sobajima H, Yoshikawa H, Toba T, Kushimoto H, Katsumata H et al. Usefulness of a highly sensitive urinary and serum IL-6 assay in patients with diabetic nephropathy. Nephron 2000; 85: 81-85.
14. Moriwaki Y, Inokuchi T, Yamamoto A, Ka T, Tsutsumi Z, Takahashi S et al. Effect of TNF-alpha inhibition on urinary albumin excretion in experimental diabetic rats. Acta Diabetol 2007; 44: 215-218.
15. Hayakawa K, Ohashi H, Yokoyama H, Yoshida G, Okada M, Minatoguchi S. Adiponectin is increased and correlated with the degree of proteinuria, but plasma leptin is not changed in patients with chronic glomerulonephritis. Nephrology 2009; 14: 327-331.
16. Norata GD, Baragetti I, Raselli S, Stucchi A, Garlaschelli K, Vettoretti S et al. Plasma adiponectin levels in chronic kidney disease patients: relation with molecular inflammatory profile and metabolic status. Nutr Metab Cardiovasc Dis 2009. e-pub ahead of print 8 April 2009; doi:10.1016/j.numecd.2009.01.011.
17. Yano Y, Hoshide S, Ishikawa J, Hashimoto T, Eguchi K, Shimada K et al. Differential impacts of adiponectin on low-grade albumi-nuria between obese and nonobese persons without diabetes. J Clin Hypertens 2007; 9: 775-782.
18. Sharma K, Ramachandrarao S, Qiu G, Usui HK, Zhu Y, Dunn SR et al. Adiponectin regulates albuminuria and podocyte function in mice. J Clin Invest 2008; 118: 1645-1656.
19. Levey AS, Coresh J, Greene T, Marsh J, Stevens LA, Kusek JW et al. Chronic Kidney Disease Epidemiology Collaboration. Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem 2007; 53: 766-772.
20. Muller B, Peri G, Doni A, Torri V, Landmann R, Bottazzi B et al. Circulating levels of the long pentraxin PTX3 correlate with severity of infection in critically ill patients. Crit Care Med 2001; 29: 1404-1407.
21. Brantsma AH, Atthobari J, Bakker SJ, de Zeeuw D, de Jong PE, Gansevoort RT. What predicts progression and regression of urinary albumin excretion in the nondiabetic population? J Am Soc Nephrol 2007; 18: 637-645.
22. Morales E, Valero MA, León M, Hernández E, Praga M. Beneficial effects of weight loss in overweight patients with chronic proteinuric nephropathies. Am J Kidney Dis 2003; 41: 319-327.
23. Solerte SB, Fioravanti M, Schifino N, Ferrari E. Effects of diet-therapy on urinary protein excretion albuminuria and renal haemodynamic function in obese diabetic patients with overt nephropathy. Int J Obes 1989; 13: 203-211.
24. Serra A, Granada ML, Romero R, Bayés B, Cantón A, Bonet J et al. The effect of bariatric surgery on adipocytokines, renal parameters and other cardiovascular risk factors in severe and very severe obesity: 1-year follow-up. Clin Nutr 2006; 25: 400-408.
25. Cirillo M, Lanti MP, Menotti A, Laurenzi M, Mancini M, Zanchetti A et al. Definition of kidney dysfunction as a cardiovascular risk factor: use of urinary albumin excretion and estimated glomer-ular filtration rate. Arch Intern Med 2008; 168: 617-624.
26. Karelis AD. Metabolically healthy but obese individuals. Lancet 2008; 372: 1281-1283.
27. Goossens GH. The role of adipose tissue dysfunction in the pathogenesis of obesity-related insulin resistance. Physiol Behav 2008; 94: 206-218.
28. Sarafidis PA. Obesity, insulin resistance and kidney disease risk: insights into the relationship. Curr Opin Nephrol Hypertens 2008; 17: 450-456.
29. Krebs DL, Hilton DJ. SOCS: physiological suppressors of cytokine signaling. J Cell Sci 2000; 113: 2813-2819.
30. Lebrun P, Van Obberghen E. SOCS proteins causing trouble in insulin action. Acta Physiol 2008; 192: 29-36.
31. Shi H, Cave B, Inouye K, Bjørbaek C, Flier JS. Overexpression of suppressor of cytokine signaling 3 in adipose tissue causes local but not systemic insulin resistance. Diabetes 2006; 55: 699-707.
32. Emanuelli B, Peraldi P, Filloux C, Chavey C, Freidinger K, Hilton DJ et al. SOCS-3 inhibits insulin signaling and is up-regulated in response to tumor necrosis factor-alpha in the adipose tissue of obese mice. J Biol Chem 2001; 276: 47944-47949.
33. Ueki K, Kondo T, Kahn CR. Suppressor of cytokine signaling 1 (SOCS-1) and SOCS-3 cause insulin resistance through inhibition of tyrosine phosphorylation of insulin receptor substrate proteins by discrete mechanisms. Mol Cell Biol 2004; 24: 5434-5446.
34. Rieusset J, Bouzakri K, Chevillotte E, Ricard N, Jacquet D, Bastard JP et al. Suppressor of cytokine signaling 3 expression and insulin resistance in skeletal muscle of obese and type 2 diabetic patients. Diabetes 2004; 53: 2232-2241.
35. Séron K, Corset L, Vasseur F, Boutin P, Gómez-Ambrosi J, Salvador J et al. Distinct impaired regulation of SOCS3 and long and short isoforms of the leptin receptor in visceral and subcutaneous fat of lean and obese women. Biochem Biophys Res Commun 2006; 348: 1232-1238.
36. Lagathu C, Bastard JP, Auclair M, Maachi M, Capeau J, Caron M. Chronic interleukin-6 (IL-6) treatment increased IL-6 secretion and induced insulin resistance in adipocyte: prevention by rosiglitazone. Biochem Biophys Res Commun 2003; 311: 372-379.
37. Mantovani A, Garlanda C, Bottazzi B, Peri G, Doni A, Martinez de la Torre Y et al. The long pentraxin PTX3 in vascular pathology. Vascul Pharmacol 2006; 45: 326-330.
38. Alberti L, Gilardini L, Zulian A, Micheletto G, Peri G, Doni A et al. Expression of long pentraxin PTX3 in human adipose tissue and its relation with cardiovascular risk factors. Atherosclerosis 2009; 202: 455-460.
39. Abderrahim-Ferkoune A, Bezy O, Chiellini C, Maffei M, Grimaldi P, Bonino F et al. Characterization of the long pentraxin PTX3 as a TNFa-induced secreted protein of adipose cells. J Lipid Res 2003; 44: 994-1000.
40. Suliman ME, Yilmaz MI, Carrero JJ, Qureshi AR, Saglam M, Ipcioglu OM et al. Novel links between the long pentraxin 3, endothelial dysfunction, and albuminuria in early and advanced chronic kidney disease. Clin J Am Soc Nephrol 2008; 3: 976-985.
41. Yilmaz MI, Axelsson J, Sonmez A, Carrero JJ, Saglam M, Eyileten T et al. Effect of renin angiotensin system blockade on pentraxin 3 levels in type-2 diabetic patients with proteinuria. Clin J Am Soc Nephrol 2009; 4: 535-541.
42. Ye J. Emerging role of adipose tissue hypoxia in obesity and insulin resistance. Int J Obesity 2009; 33: 54-66.
43. Drevon CA. Fatty acids and expression of adipokines. Biochim Biophys Acta 2005; 1740: 287-292.
44. Berndt J, Kovacs P, Ruschke K, Klöting N, Fasshauer M, Schön MR et al. Fatty acid synthase gene expression in human adipose tissue: association with obesity and type 2 diabetes. Diabetologia 2007; 50: 1472-1480.
45. Korczynska J, Stelmanska E, Nogalska A, Szolkiewicz M, Goyke E, Swierczynski J et al. Upregulation of lipogenic enzymes genes expression in white adipose tissue of rats with chronic renal failure is associated with higher level of sterol regulatory element binding protein-1. Metabolism 2004; 53: 1060-1065.
46. Szolkiewicz M, Nieweglowski T, Korczynska J, Sucajtys E, Stelmanska E, Goyke E et al. Upregulation of fatty acid synthase gene expression in experimental chronic renal failure. Metabolism 2002; 51: 1605-1610.
47. Looker HC, Krakoff J, Funahashi T, Matsuzawa Y, Tanaka S, Nelson RG et al. Adiponectin concentrations are influenced by renal function and diabetes duration in Pima Indians with type 2 diabetes. J Clin Endocrinol Metab 2004; 89: 4010-4017.